1.78 USD
▼-0.04-2.20%
盘后 2.03 0.00%
2026-09-16
市值
$3.96M
市盈率
—
EPS
-11.55
股息率
—
52 周区间
1.36 – 64.12
成交量
37.41K
Beta
-0.55
目标价
18.50
52W 低 1.3652W 高 64.12
价格走势
公司简介
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ...